Finch Therapeutics Group Inc
Change company Symbol lookup
Select an option...
FNCH Finch Therapeutics Group Inc
RCLFW Rosecliff Acquisition Equity I Warrants Exp 11 Feb 2026 *W EXP 02/11/2026
FAST Fastenal Co
UKOMW Ucommune International Equity Warrant Exp 17th Nov 2025 *W EXP 11/17/2025
KMI Kinder Morgan Inc
RSG Republic Services Inc
TGEN Tecogen Inc
EPAM Epam Systems Inc
ISLE Isleworth Healthcare Acquisition Corp

Health Care : Biotechnology | Small Cap Growth
Company profile

Finch Therapeutics Group, Inc. is a clinical-stage microbiome therapeutics company. It is engaged in leveraging its Human-First Discovery platform to develop a class of orally administered biological drugs. Its Human-First Discovery platform uses reverse translation to identify diseases of dysbiosis and to design microbiome therapeutics that address them. Its lead product candidate, CP101, is an orally administered complete microbiome therapeutic in development for the prevention of recurrent Clostridioides difficile infection (CDI). CP101, consists of a microbial community harvested from rigorously screened healthy donors that is lyophilized and formulated in orally administered capsules designed to release at the appropriate location in the gastrointestinal tract. CP101 is designed to deliver a complete microbiome, addressing the community-level dysbiosis that characterizes CDI. Its product pipeline includes FIN-211, TAK-524, and FIN-525, as well as consortia product candidates.

Day's Change
-0.05 (-1.74%)
B/A Size
Day's High
Day's Low

Today's volume of 13,168 shares is on pace to be much lighter than FNCH's 10-day average volume of 197,256 shares.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.